Artiva Biotherapeutics, Inc. ARTV Revenue from contracts outside the scope of ASC Topic 606
Revenue from contracts outside the scope of ASC Topic 606 at other companies
Other financials
Where this comes from
Reported directly by Artiva Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueNotFromContractWithCustomer.
The official record: Artiva Biotherapeutics, Inc.’s 10-K, filed March 10, 2026, on SEC EDGAR. View the filing →
Ask your AI about Artiva Biotherapeutics, Inc.'s revenue from contracts outside the scope of asc topic 606.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Artiva Biotherapeutics, Inc.'s revenue from contracts outside the scope of ASC topic 606?
- Artiva Biotherapeutics, Inc. (ARTV) reported revenue from contracts outside the scope of ASC topic 606 of $0 in Q4 2025.
- What does revenue from contracts outside the scope of ASC topic 606 mean?
- This metric represents revenue streams recognized outside the standard framework of customer contracts, such as government grants, research collaborations, or licensing arrangements that fall under different accounting guidance. It provides insight into non-core funding sources that support ongoing research and development activities. Investors use this to evaluate the company's ability to secure alternative capital or strategic partnerships beyond traditional product sales.